Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06788171 |
TitlePULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | Phase
Phase 2
|
Date Added 2025-03-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06764680 |
TitleOral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer | Phase
Phase 2
|
Date Added 2025-01-08 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06634875 |
TitleIsunakinra Alone and in Combination with Pembrolizumab in Patients with Colorectal Cancer (MSS) | Phase
Phase 2
|
Date Added 2024-10-10 |
Location
California, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06589440 |
TitlePhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase
Phase 2
|
Date Added 2024-09-19 |
Location
New Jersey, United States
Texas, United States Washington, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06566755 |
TitleCadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer | Phase
Phase 3
|
Date Added 2024-08-22 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06558773 |
TitleGSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. | Phase
Phase 2
|
Date Added 2024-08-19 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06515314 |
TitleHRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors | Phase
Phase 1
|
Date Added 2024-07-23 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06514651 |
TitleMAQ-001 in Patients With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2024-07-23 |
Location
France
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd
|
| NCT ID NCT06513221 |
TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | Phase |
Date Added 2024-07-22 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status |
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT06508307 |
TitleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2024-07-18 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|




